GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

A new study finds that the diabetes drug liraglutide significantly reduced monthly migraine days in patients with obesity and ...

The United Kingdom's health regulator is investigating weight loss jabs like Ozempic and Mounjaro after linking it to ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

Viking Therapeutics initiates VANQUISH phase 3 obesity clinical programme with GLP-1/GIP agonist VK2735: San Diego Thursday, June 26, 2025, 10:00 Hrs [IST] Viking Therapeutics, In ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new study into side effects of GLP-1 medicines ...